Torchmark (TMK) (MCK) (CNC) (CPSI) (BWA) (ASEI) Price Targets Changed

Torchmark Co. (NYSE: TMK), McKesson Co. (NYSE: MCK), Centene Co. (NYSE: CNC), Computer Programs & Systems, Inc. (NASDAQ: CPSI), BorgWarner Inc. (NYSE: BWA) and American Science And Engineering Incorporated (NASDAQ: ASEI) had their price targets adjusted by analysts.

Torchmark Co. (TMK) had its price target raised by Credit Suisse (NYSE:CS) to $41.00. They have an “Underperform” rating on the company.

McKesson Co. (MCK) had its price target lowered by Auriga to $95.00.

Centene Co. (CNC) had its price target raised by JPMorgan Chase & Co. (NYSE:JPM) to $39.00.

Computer Programs & Systems, Inc. (CPSI) had its price target raised by Auriga from $60.00 to $78.00. They have a “Hold” rating on the company.

BorgWarner Inc (BWA) had its price target raised by analysts at Citigroup (NYSE:C) to $88.00. The analysts now have a “hold” rating on the company.

American Science And Engineering Incorporated (NASDAQ: ASEI) had its price target lowered by analysts at The Benchmark Company from $90.00 to $80.00. The analysts now have a “hold” rating on the company.

Price Targets on (EXLS) (FWLT) (IPGP) (LVS) (MCK) Updated by Analysts

Analysts updated the price targets on ExlService Holdings, Inc. (NASDAQ: EXLS), Foster Wheeler Ltd. (NASDAQ: FWLT), IPG Photonics Co. (NASDAQ: IPGP), Las Vegas Sands Corp. (NYSE: LVS) and McKesson Co. (NYSE: MCK).

Deutsche Bank (NYSE:DB) raised their price target on ExlService Holdings, Inc. (EXLS) from $24.00 to $29.00. They have a “buy” rating on the company.

Barclays Capital cut their price target on Foster Wheeler Ltd. (FWLT) from $45.00 to $42.00. They have an “overweight” rating on the company.

Barclays Capital raised their price target on IPG Photonics Co. (IPGP) from $60.00 to $65.00. They have an “equal weight” rating on the company.

Barclays Capital cut their price target on Las Vegas Sands Corp. (LVS) from $52.00 to $50.00. They have an “overweight” rating on the company.

Deutsche Bank raised their price target on McKesson Co. (MCK) from $101.00 to $108.00. They have a “buy” rating on the company.

Dividend Yields for (SYK) (UNH) (ABC) (MCK) (DGX)

Indicated dividend yields for Standard & Poor's 500 Index companies Stryker Corp (SYK), UnitedHealth Group Inc (UNH), AmerisourceBergen Corp (ABC), McKesson Corp (MCK) and Quest Diagnostics Inc (DGX).

These dividend data indicate dividend yields of companies in the Standard & Poor's 500 Index as of Saturday, April 30. The yield is determined by taking the latest declared dividend, annualized and divided by the price of the stock. Payout ratios are calculated based on latest quarterly dividend paid divided by earnings.

Stryker Corp (SYK) has a dividend yield of 1.22 percent on a declared dividend of $0.18. The payout ratio is 22.8 percent.

UnitedHealth Group Inc (UNH) has a dividend yield of 1.01 percent on a declared dividend of $0.12. The payout ratio is 10.2 percent.

AmerisourceBergen Corp (ABC) has a dividend yield of 0.98 percent on a declared dividend of $0.10. The payout ratio is 12.8 percent.

McKesson Corp (MCK) has a dividend yield of 0.87 percent on a declared dividend of $0.18. The payout ratio is 29.5 percent.

Quest Diagnostics Inc (DGX) has a dividend yield of 0.71 percent on a declared dividend of $0.10. The payout ratio is 11.4 percent.

McKesson (NYSE:MCK) EPS Estimates Raised on US Oncology Acquisition

The acquisition of US Oncology by McKesson (NYSE:MCK) will help boost earnings for full year 2012 through 2015, says UBS (NYSE:UBS).

UBS commented, "The US Oncology acquisition closed on December 30th, and we are now including the USON operations in our MCK model. Based on our calculations, we expect the transaction to be $0.03 accretive to EPS in F2012. The US Oncology operations have witnessed some ‘ups and downs’ over the past several years, but most of the issues were macro-related and thus out of the control of USON mgmt. Thus, we assume resumption to more normalized profit growth patterns for C2011-14...We are raising our F2012-15 EPS estimates by $0.03, $0.08, $0.13, and $0.20, respectively to reflect the expected accretion from the USON acquisition."

UBS reiterates a "Buy" rating on McKesson, which closed Wednesday at $73.99, losing $0.48, or 0.64 percent. UBS raised their price target on MCK from $82 to $84.

McKesson (NYSE:MCK) Ready to Defend US Oncology Acquisition Attempt

The attempt to acquire US Oncology Holdings Inc. by McKesson for $560 million has been put on hold by the Supreme Court of the State of New York in response to a case brought against it by the Cancer Clinics of Excellence, a network of oncology practices.

The Cancer Clinics of Excellence claims the deal is a breach of an agreement between them and McKesson.

Barclays (NYSE:BCS) said, "From our discussions with the company, McKesson believes that the order may have been granted hastily (our words) and plans to appeal the order in the next few days. MCK continues to expect to close on the USO acquisition according to its original 12/31/10 date noted in its merger agreement. We also highlight that based on our discussions with the company, while either party could walk away from the merger (with no break-up fee in our understanding), the company does not anticipate that occurring and intends to continue with the acquisition. Should closing be delayed, MCK intends to defend its position at the January 10th hearing."

Barclays maintains an "Overweight" on McKesson, which last closed at $70.86, down $0.11, or 0.15 percent. Barclays has a price target on them of $76.